查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1722862

基因治疗市场规模、份额、趋势及预测（按基因类型、载体类型、递送方式、应用和地区），2025 年至 2033 年

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球基因治疗市场规模价值 58 亿美元。展望未来， IMARC Group估计到 2033 年市场规模将达到 179 亿美元，2025 年至 2033 年的复合年增长率为 13.3%。北美目前占据市场主导地位，到 2024 年市占率将超过 56%。北美市场受到强大的医疗保健基础设施、不断增加的研究营运投资、先进的监管框架以及促进创新的领先生物技术公司的推动。

基因治疗市场分析：

市场成长和规模：受基因异常和罕见疾病盛行率上升的推动，该行业正在迅速扩张。此外，製药企业正在增加对研发活动的投资，这对市场产生了积极影响。

技术进步：病毒载体技术的发展正在提高基因治疗的有效性和安全性。此外，CRISPR-Cas9技术提高了基因编辑能力，进一步加速了基因治疗市场统计。

产业应用：基因疗法用于治疗多种疾病，包括癌症、遗传问题和自体免疫疾病。体外基因疗法，在体外操纵细胞，在治疗特定遗传疾病方面越来越受欢迎。

地理趋势：根据 IMARC 的基因疗法市场统计数据，北美凭藉其强大的医疗保健基础设施和发达的生物技术部门占据市场主导地位。然而，在庞大患者群体的推动下，亚太地区正成为一个快速扩张的市场。

竞争格局：领先的企业正在进行全面的临床研究，以开发并获得针对各种疾病（包括罕见基因异常和癌症）的新型基因治疗方法的监管批准。市场上一些主要的参与者包括 Abeona Therapeutics Inc.、Adaptimmune Therapeutics plc、Adverum Biotechnologies Inc.、Amgen Inc.、Astellas Pharma Inc.、Biogen Inc.、Bluebird Bio Inc.、Mustang Bio Inc. (Fortress Biotech Inc.)、Novartis AGager、Oraptisc.

挑战与机会：虽然该行业面临监管限制和高昂研究成本等限制，但它也期望能够增加除罕见疾病之外的用途并研究新的交付方式。

未来展望：基因治疗市场前景预计是正面的，对基因异常和罕见疾病的新疗法的需求不断增长。此外，针对独特患者特征的个人化基因疗法预计将推动市场扩张。

基因治疗市场趋势：

病毒载体技术的进展

病毒载体技术的不断进步和创新是推动市场成长的重要因素。病毒载体被用作运载工具，将治疗基因引入患者的细胞。该技术的最新进展大大提高了基因治疗的安全性和有效性。这些发展包括创建更具体、更集中的病毒载体，例如腺相关病毒 (AAV) 和慢病毒，其中 AAV 因其能够以最小的免疫反应和损伤运输遗传物质而越来越受欢迎。此外，根据基因治疗市场概况，研究人员正专注于开发可能携带更大遗传负荷的病毒载体，扩大可治癒疾病的范围。这些技术创新不仅提高了基因治疗的疗效，而且最大限度地减少了副作用的可能性，使患者更加安全。因此，病毒载体技术的进步正在加速基因治疗对更广泛的医疗问题的接受和疗效。例如，默克集团 (MERCK KGaA) 的 VirusExpress 293 腺相关病毒 (AAV) 生产平台提供完整的病毒载体製造，包括 AAV 和慢病毒载体。此外，Catalent Inc. 推出了 UpTempo Virtuoso 平台流程，用于开发和製造腺相关病毒 (AAV) 载体。

研发投资与资金

基因治疗研究和开发（R&D）工作不断增长的投资和资金正在推动市场扩张。製药公司、生技公司和政府机构正在投入大量资源开发基因治疗技术和疗法。基因治疗在解决未满足的医疗需求和提供长期利益方面具有巨大潜力，正在吸引大量资金。大型製药公司要么收购基因治疗新创公司，要么建立自己的基因治疗部门以加快研究速度，这对基因治疗市场前景产生了积极影响。此外，政府补助和激励措施鼓励学术机构和研究公司进行基因治疗实验。美国的《孤儿药法案》以及其他国家的类似立法都为罕见疾病药物的开发提供了诱因。例如，囊性纤维化基金会报告已投资 SalioGen Therapeutics，以支持该公司对囊性纤维化新型基因疗法的临床前研究。 Salonen 的基因编码方法旨在开启、关闭或修改基因组中任何基因的功能。

遗传性疾病和罕见疾病的盛行率不断上升

基因异常和罕见疾病的盛行率不断上升，推动着市场的成长。许多此类疾病几乎没有或根本没有有效的治疗选择，因此基因疗法成为有趣的替代方法。随着我们对遗传学认识的不断进步，越来越多的人得到诊断，对新型药物的需求也不断增长。此外，基因疗法能够透过修復或替换缺陷基因来治疗许多疾病的根本原因。这包括肌肉营养不良症、囊性纤维化和其他遗传性代谢失调等疾病。製药和生物技术企业正在投资基因疗法研究以满足不断增长的医疗需求，从而促进该领域的市场扩张和改善。例如，根据美国疾病管制与预防中心关于脊髓性肌肉萎缩症 (SMA) 的文章，SMA 是一种遗传性疾病，每 10,000 人中约有 1 人患有此病。因此，它是最常见的罕见疾病之一。

支持性监管环境

一些国家的监管机构，尤其是美国食品药物管理局（FDA）和欧洲药品管理局（EMA），都认识到基因疗法满足基本医疗需求的潜力。因此，他们创建了结构并加速了基因治疗的研究和批准。此外，快速通道指定、突破性治疗指定和孤儿药地位是基因治疗候选药物可获得的监管措施之一。这些指定简化了临床试验程序，缩短了开发时间表，并鼓励企业参与基因治疗研究。例如，美国 FDA 批准了 Zynteglo（betibeglogene autotemcel），这是第一个用于治疗成人和儿童β-地中海贫血患者的基于细胞的基因疗法。由于基因疗法的发展，此类批准预计将推动市场成长。

基因治疗市场细分：

依基因类型分类：

抗原

细胞因子

肿瘤抑制因子

自杀基因

不足

生长因子

受体

其他的

抗原基因是基因治疗中的关键环节，尤其是在癌症免疫治疗中。这些基因编码肿瘤特异性抗原或与传染性病原体相关的抗原。透过将抗原基因引入患者的细胞，可以活化免疫系统来识别和瞄准癌细胞或病原体。它们还能实现个人化癌症治疗，透过针对患者特定的抗原来实现更有效、更有针对性的免疫反应。例如，Imugene 报告了与美国新泽西州凯尼尔沃思默克公司 (Merck & Co., Inc.) 的商标 MSD 达成的一项新的临床试验合作和供应协议，以评估 Imugene 的 HER-Vaxx（一种 B 细胞激活免疫疗法）与 MSD 的抗 PD-1 疗法 pembrolizumab (KEYmbrolizumab (KEYAUDA)。

依向量类型分类：

病毒载体

腺病毒

慢病毒

逆转录病毒

腺相关病毒

单纯疱疹病毒

痘病毒

痘苗病毒

其他的

非病毒技术

裸载体和质粒载体

基因枪

电穿孔

脂质体转染

其他的

病毒载体在产业中占有最大的份额。

病毒载体，例如腺相关病毒 (AAV) 和慢病毒，由于能够有效地将治疗基因递送到目标细胞中而越来越受到关注。 AAV 因其安全性和将遗传物质整合到宿主基因组中的能力而受到青睐。它们广泛用于各种基因治疗应用，包括治疗遗传疾病、罕见疾病和某些类型的癌症。病毒载体技术的持续研究和进步正在推动这一领域的成长，许多临床试验和批准的疗法都利用病毒载体。例如，美国FDA加速批准了慢病毒载体基因疗法SKYSONA，证实可减缓4-17岁男孩的神经退化性功能障碍或活动性大脑肾上腺脑白质营养不良的进展。

依交付方式分类：

体内基因治疗

体外基因治疗

体内基因治疗涉及将治疗基因或遗传物质直接输送到患者体内。此方法旨在修改或纠正患者自然生理环境中组织或器官内的基因缺陷。体内基因治疗方法通常利用病毒载体（例如腺相关病毒（AAV）或慢病毒）来运输治疗基因。基因治疗的这一部分通常用于需要全身性治疗的疾病，例如某些类型的遗传性疾病或体内目标组织易于接近的疾病。例如，基因补充疗法的最新进展正在扩大治疗神经系统疾病的选择。在可用的递送载体中，腺相关病毒（AAV）通常是最受欢迎的载体。

按应用分类：

肿瘤疾病

罕见疾病

心血管疾病

神经系统疾病

传染病

其他的

肿瘤疾病占据了大部分市场。

基因治疗对多种癌症，包括实体肿瘤和血液系统恶性肿瘤，均有治疗效果。方法包括引入肿瘤抑制基因和活化免疫系统对抗癌细胞。 CAR-T 细胞疗法是一种基因疗法，因其在治疗某些类型的白血病和淋巴瘤方面的成功而受到关注。肿瘤疾病基因疗法的持续研发活动正在推动市场成长。例如，美国 FDA 批准了 Abecma（idecabtagene vicleucel），这是一种基于细胞的基因疗法，用于治疗对至少四线（不同类型）治疗无反应或病情復发的多发性骨髓瘤成年患者。 Abecma 是 FDA 批准的首个用于治疗多发性骨髓瘤的细胞基因疗法。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美引领市场，占据最大的基因治疗市场。

市场研究报告也对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告显示，北美占据最大的市场份额。

北美拥有强大的医疗保健基础设施、成熟的生物技术产业以及对基因治疗研发（R&D）的大量投资。有利的监管政策，包括快速通道指定和孤儿药地位，正在加速基因疗法的批准和商业化。基因治疗市场的关键参与者总部设在北美，为该地区在基因治疗创新领域的领导地位做出了贡献。例如，根据美国国立卫生研究院（NIH）的最新消息，NIH、美国食品药物管理局、十家製药公司和五个非营利组织已合作加速为 3,000 万名患有罕见疾病的美国人开发基因疗法。预计这些措施将增加对基因治疗的需求，进而促进市场成长。

竞争格局：

目前，主要产业竞争对手正在参与多项策略性措施。这些公司透过研究、收购和合作不断扩大其基因治疗组合。他们正在进行全面的临床研究，以开发并获得监管部门的批准，用于治疗多种疾病，包括罕见的基因异常和癌症。此外，他们还投资製造设施以提高产量并确保更多的患者能够获得基因治疗。此外，这些行业巨头正在与学术机构和小型生物技术企业合作，以促进创新并改进基因治疗技术。

市场研究报告对竞争格局进行了全面的分析。也提供了所有主要公司的详细资料。市场中的一些主要参与者包括：

Abeona治疗公司

Adaptimmune Therapeutics plc

Adverum 生技公司

安进公司

安斯泰来製药公司

百健公司

蓝鸟生物公司

Mustang Bio公司（Fortress Biotech公司）

诺华公司

Orchard Therapeutics plc

UniQure NV

Voyager Therapeutics公司

（请注意，这只是关键参与者的部分列表，完整列表在报告中提供。）

基因治疗市场新闻：

2023 年 1 月：Spark Therapeutics 与 Neurochase 建立策略合作关係，开发 Neurochase 独特的传递技术，用于治疗中枢神经系统罕见疾病的选择性基因治疗。根据该协议，Neurochase 将向 Spark 的顶级 AAV 平台贡献其在直接药物传输技术方面的丰富知识。

2023 年 1 月：Voyager Therapeutics 和 Neurocrine Biosciences 达成策略合作，旨在实现 Voyager 的 GBA1 计划以及其他针对神经系统疾病的下一代基因疗法的商业化和开发。

2023 年 6 月：美国 FDA 核准 Sarepta 使用 ELEVIDYS 基因疗法治疗 4-5 岁儿童的 DMD。

2023 年 5 月：Krystal Biotech 的 VYJUVEK 基因疗法获得批准，用于治疗营养不良性大疱性表皮鬆解症。

2023 年 12 月：瑞士治疗产品管理局核准 Libmeldy 用于治疗早发性异染性脑白质营养不良症。

2024 年 1 月：Biogen 和 Ginkgo Bioworks 宣布完成涉及基于 AAV 的载体的基因治疗合作。预计这将在未来几年推动对基因疗法的需求。

本报告回答的关键问题

  • 什么是基因治疗
  • 全球基因疗法市场有多大
  • 2025-2033年全球基因治疗市场的预期成长率是多少
  • 推动全球基因治疗市场的关键因素有哪些
  • 根据基因类型，全球基因治疗市场的主要细分领域是什么
  • 根据载体类型，全球基因治疗市场的主要细分领域是什么
  • 根据交付方式，全球基因治疗市场的主要细分领域是什么
  • 根据应用，全球基因治疗市场的主要细分领域是什么
  • 全球基因治疗市场的主要区域有哪些
  • 10.全球基因治疗市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 什么是基因治疗？全球基因治疗市场有多大？
  • 2025-2033年全球基因治疗市场的预期成长率是多少？
  • 推动全球基因治疗市场发展的关键因素有哪些？
  • 根据基因类型，全球基因治疗市场的主要部分是什么？
  • 根据载体类型，全球基因治疗市场的主要部分是什么？
  • 根据交付方式，全球基因治疗市场的主要部分是什么？
  • 根据应用，全球基因治疗市场的主要部分是什么？
  • 全球基因治疗市场的主要区域有哪些？
  • 全球基因治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球基因治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依基因类型

  • 抗原
  • 细胞因子
  • 肿瘤抑制因子
  • 自杀基因
  • 不足
  • 生长因子
  • 受体
  • 其他的

第七章：市场区隔：依向量类型

  • 病毒载体
    • 关键部分
      • 腺病毒
      • 慢病毒
      • 逆转录病毒
      • 腺相关病毒
      • 单纯疱疹病毒
      • 痘病毒
      • 痘苗病毒
      • 其他的
  • 非病毒技术
    • 关键部分
      • 裸载体和质粒载体
      • 基因枪
      • 电穿孔
      • 脂质体转染
      • 其他的

第八章：市场区隔：依交付方式

  • 体内基因治疗
  • 体外基因治疗

第九章：市场区隔：依应用

  • 肿瘤疾病
  • 罕见疾病
  • 心血管疾病
  • 神经系统疾病
  • 传染病
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics plc
    • Adverum Biotechnologies Inc.
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.
    • Bluebird Bio Inc.
    • Mustang Bio Inc. (Fortress Biotech Inc.)
    • Novartis AG
    • Orchard Therapeutics plc
    • UniQure NV
    • Voyager Therapeutics Inc.
Product Code: SR112025A5026

The global gene therapy market size was valued at USD 5.8 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 17.9 Billion by 2033, exhibiting a CAGR of 13.3% from 2025-2033. North America currently dominates the market, holding a market share of over 56% in 2024. The North American market is driven by robust healthcare infrastructure, rising investments in research operations, advanced regulatory frameworks, and the presence of leading biotechnology firms fostering innovation.

Gene Therapy Market Analysis:

Market Growth and Size: The industry is expanding rapidly, fueled by the rising prevalence of genetic abnormalities and rare diseases. Additionally, pharmaceutical businesses are increasingly investing in research and development (R&D) activities, which are positively impacting the market.

Technological Advancements: Developments in viral vector technology are enhancing the efficacy and safety of gene therapy delivery. Moreover, CRISPR-Cas9 technology improves gene editing capabilities, which further accelerates gene therapy market statistics.

Industry Applications: Gene therapy is used to treat a variety of ailments, including cancer, genetic problems, and autoimmune conditions. Ex vivo gene therapy, in which cells are manipulated outside the body, is gaining popularity for treating specific genetic illnesses.

Geographical Trends: As per the gene therapy market statistics by IMARC, North America dominates the market, owing to its strong healthcare infrastructure and developed biotechnology sector. However, Asia Pacific is emerging as a rapidly expanding market, propelled by a big patient population.

Competitive Landscape: Leading players are conducting comprehensive clinical studies to develop and get regulatory clearance for novel gene treatments aimed at a variety of ailments, including rare genetic abnormalities and cancer. Some of the key players in the market include Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V., Voyager Therapeutics Inc., etc.

Challenges and Opportunities: While the industry confronts constraints like regulatory limitations and high research costs, it also expects possibilities for increasing uses beyond rare disorders and investigating novel delivery modalities.

Future Outlook: The gene therapy market outlook is expected to be positive, with rising demand for novel therapies for genetic abnormalities and uncommon illnesses. Furthermore, individualized gene therapy tailored to unique patient characteristics is projected to drive market expansion.

Gene Therapy Market Trends:

Advancements in Viral Vector Technology

Continuous progress and innovation in viral vector technology are important factors driving market growth. Viral vectors are used as delivery vehicles to introduce therapeutic genes into the cells of patients. Recent advances in this technique have greatly improved the safety and efficacy of gene therapy therapies. These developments include the creation of more specific and focused viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, with AAVs gaining popularity due to their ability to transport genetic material with minimal immune reaction and damage. Furthermore, as per the gene therapy market overview, researchers are focusing on developing viral vectors that may carry bigger genetic payloads, broadening the range of curable disorders. These technical innovations not only increase the efficacy of gene treatments but also minimize the likelihood of adverse effects, making them safer for patients. As a result, the advancement of viral vector technology is accelerating the acceptance and efficacy of gene therapy treatments for a broader range of medical problems. For instance, MERCK KGaA, the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, offers full viral vector manufacturing, including AAV and lentiviral vectors. Additionally, Catalent Inc. launched UpTempo Virtuoso platform process for the development and manufacturing of adeno-associated viral (AAV) vectors.

Investment And Funding in Research and Development

The growing investments and funding for gene therapy research and development (R&D) efforts are driving market expansion. Pharmaceutical businesses, biotechnology firms, and government agencies are putting major resources into developing gene therapy technologies and therapeutics. Gene treatments have a strong potential for addressing unmet medical needs and providing long-term benefits, which is drawing significant funding. Major pharmaceutical corporations are either purchasing gene therapy startups or building their own gene therapy sections to speed up research, which is positively impacting the gene therapy market outlook. Furthermore, government subsidies and incentives motivate academic institutions and research firms to conduct gene therapy experiments. The Orphan Drug Act in the United States, as well as comparable legislation in other countries, gives incentives for the development of rare illness medicines. For instance, the Cystic Fibrosis Foundation reported investing in SalioGen Therapeutics to support the company's preclinical research into novel gene therapy for cystic fibrosis. Salonen's Gene Coding approach is designed to turn on, turn off, or modify the function of any gene in the genome.

Rising Prevalence of Genetic Disorders and Rare Diseases

The rising prevalence of genetic abnormalities and rare illnesses is propelling the market growth. Many of these diseases have little or no effective treatment choices, making gene therapy an intriguing alternative. As our understanding of genetics advances, more people are diagnosed, and the demand for novel medicines grows. Moreover, gene therapy has the ability to treat the underlying causes of many disorders by repairing or replacing defective genes. This comprises illnesses including muscular dystrophy, cystic fibrosis, and other hereditary metabolic disorders. Pharmaceutical and biotechnology businesses are investing in gene therapy research to fulfill this expanding medical demand, resulting in market expansion and improvements in the area. For instance, as per the United States Center for Disease Control and Prevention article on spinal muscular atrophy (SMA), SMA is a genetic disorder that affects around 1 in every 10,000 people. Therefore, it is one of the most common rare diseases.

Supportive Regulatory Environment

Regulatory organizations in several countries, especially the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), recognize the potential of gene therapy to address essential medical needs. Consequently, they have created structures and accelerated the research and approval of gene treatments. Additionally, fast-track designations, breakthrough treatment designations, and orphan drug status are among the regulatory measures available to gene therapy candidates. These designations ease the clinical trial procedure, shorten development schedules, and encourage corporations to participate in gene therapy research. For instance, the U.S. FDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for treating adult and pediatric patients with beta-thalassemia. Such approvals are expected to drive market growth due to the rise in the development of gene therapies.

Gene Therapy Market Segmentation:

Breakup by Gene Type:

Antigen

Cytokine

Tumor Suppressor

Suicide Gene

Deficiency

Growth Factors

Receptors

Others

Antigen genes are a critical segment in gene therapy, especially in the context of cancer immunotherapy. These genes code for tumor-specific antigens or antigens associated with infectious agents. By introducing antigen genes into the cells of the patients, the immune system can be activated to recognize and target cancer cells or pathogens. They also enable personalized cancer treatments, where patient-specific antigens can be targeted for a more effective and targeted immune response. For instance, Imugene reported a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in patients with HER-2 positive gastric cancer.

Breakup by Vector Type:

Viral Vector

Adenoviruses

Lentiviruses

Retroviruses

Adeno-Associated Virus

Herpes Simplex Virus

Poxvirus

Vaccinia Virus

Others

Non-Viral Techniques

Naked and Plasmid Vectors

Gene Gun

Electroporation

Lipofection

Others

Viral vector holds the largest share in the industry.

Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, are gaining traction due to their efficient delivery of therapeutic genes into target cells. AAVs are favored for their safety profile and ability to integrate genetic material into the host genome. They are widely used for a variety of gene therapy applications, including treating genetic disorders, rare diseases, and certain types of cancer. Ongoing research and advancements in viral vector technology are driving the growth of this segment, with numerous clinical trials and approved therapies utilizing viral vectors. For instance, the U.S. FDA granted approval at an accelerated pace for SKYSONA- a lentiviral vector gene therapy shown to slow the progression of neurodegenerative dysfunction, or active cerebral adrenoleukodystrophy in boys with the age range of 4-17.

Breakup by Delivery Method:

In-Vivo Gene Therapy

Ex-Vivo Gene Therapy

In-vivo gene therapy involves the direct delivery of therapeutic genes or genetic material into the body of the patient. This approach aims to modify or correct genetic defects within the tissues or organs of patients in their natural physiological environment. In-vivo gene therapy methods typically utilize viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, to transport the therapeutic genes. This segment of gene therapy is often used for diseases that require systemic treatment, such as certain types of inherited disorders or conditions where the target tissue is easily accessible within the body. For instance, recent advancements in gene supplementation therapy are expanding the options for the treatment of neurological disorders. Among the available delivery vehicles, adeno-associated virus (AAV) is often the favored vector.

Breakup by Application:

Oncological Disorders

Rare Diseases

Cardiovascular Diseases

Neurological Disorders

Infectious Disease

Others

Oncological disorders account for the majority of the market share.

Gene therapy is effective in the treatment of various cancers, including solid tumors and hematological malignancies. Approaches range from introducing tumor-suppressing genes to activating the immune system against cancer cells. CAR-T cell therapy, a type of gene therapy, is gaining traction for its success in treating certain types of leukemia and lymphoma. The ongoing research and development (R&D) activities of gene therapies for oncological disorders are impelling the market growth. For instance, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after at least four last lines (different types) of treatment. Abecma is the first cell-based gene therapy approved by the FDA for treating multiple myeloma.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest gene therapy market share.

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a robust healthcare infrastructure, a well-established biotechnology industry, and significant investment in gene therapy research and development (R&D). Favorable regulatory policies, including fast-track designations and orphan drug status, are accelerating the approval and commercialization of gene therapies. Key players in the gene therapy market are headquartered in North America, contributing to the leadership of the region in gene therapy innovations. For instance, as per an update by the National Institutes of Health (NIH), the NIH, USFDA, ten pharmaceutical companies, and five non-profit organizations have partnered to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are anticipated to increase the demand for gene therapy, thereby contributing to market growth.

Competitive Landscape:

Key industry competitors are currently involved in a number of strategic initiatives. These firms are constantly growing their gene therapy portfolios via research, acquisitions, and collaborations. They are undertaking comprehensive clinical studies to develop and get regulatory clearance for novel gene treatments that will treat a variety of ailments, including rare genetic abnormalities and cancer. In addition, they are investing in manufacturing facilities to increase output and ensure gene treatments are available to a larger patient population. Furthermore, these industry heavyweights are pursuing collaborations with academic institutions and smaller biotech businesses to promote innovation and improve gene therapy technology.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abeona Therapeutics Inc.

Adaptimmune Therapeutics plc

Adverum Biotechnologies Inc.

Amgen Inc.

Astellas Pharma Inc.

Biogen Inc.

Bluebird Bio Inc.

Mustang Bio Inc. (Fortress Biotech Inc.)

Novartis AG

Orchard Therapeutics plc

UniQure N.V.

Voyager Therapeutics Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Gene Therapy Market News:

January 2023: Spark Therapeutics and Neurochase established a strategic collaboration to develop Neurochase's unique delivery technology for use with selected gene treatments for rare disorders in the CNS. In this agreement, Neurochase will contribute its extensive knowledge in direct drug delivery technology to Spark's premier AAV platform.

January 2023: Voyager Therapeutics and Neurocrine Biosciences entered into a strategic collaboration for the commercialization & development of Voyager's GBA1 program and other next-generation gene therapies for neurological diseases.

June 2023: The U.S. FDA granted approval to Sarepta for ELEVIDYS gene therapy to treat DMD in children of age 4-5 years.

May 2023: Krystal Biotech was granted approval for VYJUVEK gene therapy for Dystrophic Epidermolysis Bullosa treatment.

December 2023: Swiss Agency for Therapeutic Products granted approval to Libmeldy for the treatment of early-onset metachromatic leukodystrophy.

January 2024: Biogen and Ginkgo Bioworks announced that they have completed the gene therapy collaboration involving AAV-based vectors. This is expected to fuel the demand for gene therapies in the coming years.

Key Questions Answered in This Report

  • 1.What is gene therapy?
  • 2.How big is the global gene therapy market?
  • 3.What is the expected growth rate of the global gene therapy market during 2025-2033?
  • 4.What are the key factors driving the global gene therapy market?
  • 5.What is the leading segment of the global gene therapy market based on gene type?
  • 6.What is the leading segment of the global gene therapy market based on vector type?
  • 7.What is the leading segment of the global gene therapy market based on delivery method?
  • 8.What is the leading segment of the global gene therapy market based on application?
  • 9.What are the key regions in the global gene therapy market?
  • 10.Who are the key players/companies in the global gene therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gene Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Gene Type

  • 6.1 Antigen
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cytokine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Tumor Suppressor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Suicide Gene
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Deficiency
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Growth Factors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Receptors
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Vector Type

  • 7.1 Viral Vector
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Adenoviruses
      • 7.1.2.2 Lentiviruses
      • 7.1.2.3 Retroviruses
      • 7.1.2.4 Adeno-Associated Virus
      • 7.1.2.5 Herpes Simplex Virus
      • 7.1.2.6 Poxvirus
      • 7.1.2.7 Vaccinia Virus
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Non-Viral Techniques
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Naked and Plasmid Vectors
      • 7.2.2.2 Gene Gun
      • 7.2.2.3 Electroporation
      • 7.2.2.4 Lipofection
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Delivery Method

  • 8.1 In-Vivo Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ex-Vivo Gene Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Oncological Disorders
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rare Diseases
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Cardiovascular Diseases
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Neurological Disorders
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Infectious Disease
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Others
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abeona Therapeutics Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Adaptimmune Therapeutics plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Adverum Biotechnologies Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Amgen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Astellas Pharma Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Biogen Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Bluebird Bio Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Mustang Bio Inc. (Fortress Biotech Inc.)
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Orchard Therapeutics plc
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 UniQure N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
    • 15.3.12 Voyager Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials

List of Figures

  • Figure 1: Global: Gene Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Gene Therapy Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Gene Therapy Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Gene Therapy Market: Breakup by Gene Type (in %), 2024
  • Figure 5: Global: Gene Therapy Market: Breakup by Vector Type (in %), 2024
  • Figure 6: Global: Gene Therapy Market: Breakup by Delivery Method (in %), 2024
  • Figure 7: Global: Gene Therapy Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Gene Therapy Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Gene Therapy (Antigen) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Gene Therapy (Antigen) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Gene Therapy (Cytokine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Gene Therapy (Cytokine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Gene Therapy (Tumor Suppressor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Gene Therapy (Tumor Suppressor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Gene Therapy (Suicide Gene) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Gene Therapy (Suicide Gene) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Gene Therapy (Deficiency) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Gene Therapy (Deficiency) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Gene Therapy (Growth Factors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Gene Therapy (Growth Factors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Gene Therapy (Receptors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Gene Therapy (Receptors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Gene Therapy (Other Gene Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Gene Therapy (Other Gene Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Gene Therapy (Viral Vector) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Gene Therapy (Viral Vector) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Gene Therapy (Non-Viral Techniques) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Gene Therapy (Non-Viral Techniques) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Gene Therapy (In-Vivo Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Gene Therapy (In-Vivo Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Gene Therapy (Oncological Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Gene Therapy (Oncological Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Gene Therapy (Rare Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Gene Therapy (Rare Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Gene Therapy (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Gene Therapy (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Gene Therapy (Neurological Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Gene Therapy (Neurological Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Gene Therapy (Infectious Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Gene Therapy (Infectious Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Gene Therapy (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Gene Therapy (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia-Pacific: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia-Pacific: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Gene Therapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Gene Therapy Market: Breakup by Country (in %), 2024
  • Figure 93: Middle East and Africa: Gene Therapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Gene Therapy Industry: SWOT Analysis
  • Figure 95: Global: Gene Therapy Industry: Value Chain Analysis
  • Figure 96: Global: Gene Therapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gene Therapy Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Gene Therapy Market Forecast: Breakup by Gene Type (in Million USD), 2025-2033
  • Table 3: Global: Gene Therapy Market Forecast: Breakup by Vector Type (in Million USD), 2025-2033
  • Table 4: Global: Gene Therapy Market Forecast: Breakup by Delivery Method (in Million USD), 2025-2033
  • Table 5: Global: Gene Therapy Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Gene Therapy Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Gene Therapy Market: Competitive Structure
  • Table 8: Global: Gene Therapy Market: Key Players